Print

Purpose

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion Criteria

  • This is not applicable to this study

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Pirtobrutinib (Arm A) 		Participants receive pirtobrutinib orally
  • Drug: Pirtobrutinib
    Administered orally
    Other names:
    • LY3527727
Experimental
Idelalisib (Arm B) 		Participants receive idelalisib orally
  • Drug: Idelalisib
    Administered orally

Recruiting Locations

Mitchell Cancer Institute
Mobile, Alabama 36693
Contact:
334-660-5108

Cancer Specialists, LLC
Jacksonville, Florida 32256
Contact:
904-538-4488

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York 10065-6007
Contact:
646-608-4273

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.